GlassScriptPhysician profile
Melissa Alsina
NPI 1184656746
$63,885.28
in general payments reported to CMS, 2019-2025
19 companies · $4,815 in 2025
The $4,815 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $14K · 2021: $12K · 2022: $2,671 · 2023: $4,156 · 2024: $9,742 · 2025: $4,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $2,507 · Travel and Lodging: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,688.00 |
| Food and Beverage | $2,506.76 |
| Travel and Lodging | $518.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19,121.99 | 2019-2023 | Abecma, Pomalyst |
| Legend Biotech USA INC. | $8,632.00 | 2024 | Carvykti |
| Janssen Pharmaceuticals, INC | $8,480.89 | 2019 | |
| Glaxosmithkline, LLC. | $6,431.02 | 2019-2020 | |
| Genzyme Corporation | $5,710.67 | 2022-2025 | |
| Janssen Biotech, INC. | $5,576.35 | 2019-2025 | Darzalex, Carvykti, Talvey |
| Janssen Global Services, LLC | $4,200.00 | 2025 | Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $3,095.00 | 2020-2023 | Ninlaro |
| Karyopharm Therapeutics INC. | $1,550.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $585.55 | 2021-2024 | Tecvayli |
| Boston Scientific Corporation | $161.09 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $117.90 | 2022 | |
| Kite Pharma, INC. | $100.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $62.82 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $60.00 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Alsina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.